246 related articles for article (PubMed ID: 29772978)
1. Outcomes of the addition of pasireotide to traditional adrenal-directed treatment for dogs with pituitary-dependent hyperadrenocorticism secondary to macroadenoma: 9 cases (2013-2015).
Lottati M; Bruyette DS
J Am Vet Med Assoc; 2018 Jun; 252(11):1403-1408. PubMed ID: 29772978
[TBL] [Abstract][Full Text] [Related]
2. Pituitary macroadenomas and macroadenocarcinomas in dogs treated with mitotane for pituitary-dependent hyperadrenocorticism: 13 cases (1981-1986).
Nelson RW; Ihle SL; Feldman EC
J Am Vet Med Assoc; 1989 Jun; 194(11):1612-7. PubMed ID: 2753785
[TBL] [Abstract][Full Text] [Related]
3. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Nelson RW; Feldman MS; Farver TB
J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
[TBL] [Abstract][Full Text] [Related]
4. Concurrent pituitary and adrenal tumors in dogs with hyperadrenocorticism: 17 cases (1978-1995).
Greco DS; Peterson ME; Davidson AP; Feldman EC; Komurek K
J Am Vet Med Assoc; 1999 May; 214(9):1349-53. PubMed ID: 10319177
[TBL] [Abstract][Full Text] [Related]
5. Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism.
Feldman EC; Bruyette DS; Nelson RW; Farver TB
J Am Vet Med Assoc; 1990 Jul; 197(1):71-8. PubMed ID: 2370223
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
Woolcock AD; Bugbee AC; Creevy KE
J Am Vet Med Assoc; 2016 Apr; 248(7):814-21. PubMed ID: 27003023
[TBL] [Abstract][Full Text] [Related]
7. Effect of pituitary-dependent hypercortisolism on the survival of dogs treated with radiotherapy for pituitary macroadenomas.
Rapastella S; Morabito S; Sharman M; Benoit J; Schiavo L; Morris J; Dobson JM; Scudder CJ
J Vet Intern Med; 2023; 37(4):1331-1340. PubMed ID: 37218395
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
9. One-year follow-up evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism.
Bertoy EH; Feldman EC; Nelson RW; Dublin AB; Reid MH; Feldman MS
J Am Vet Med Assoc; 1996 Apr; 208(8):1268-73. PubMed ID: 8635969
[TBL] [Abstract][Full Text] [Related]
10. Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007).
Lien YH; Huang HP
J Am Vet Med Assoc; 2008 Dec; 233(12):1896-901. PubMed ID: 19072605
[TBL] [Abstract][Full Text] [Related]
11. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
12. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Ruckstuhl NS; Nett CS; Reusch CE
Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
[TBL] [Abstract][Full Text] [Related]
13. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
Teshima T; Matsumoto H; Okusa T; Uchiyama R; Koyama H
PLoS One; 2016; 11(11):e0166267. PubMed ID: 27824928
[TBL] [Abstract][Full Text] [Related]
14. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
15. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
[TBL] [Abstract][Full Text] [Related]
19. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
Angles JM; Feldman EC; Nelson RW; Feldman MS
J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
[TBL] [Abstract][Full Text] [Related]
20. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism.
Galac S; Buijtels JJCWM; Mol JA; Kooistra HS
Vet J; 2010 Jan; 183(1):75-80. PubMed ID: 19042143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]